NT 10-Q 1 tm2214335-3_nt10q.htm NT 10-Q






Washington, D.C. 20549



SEC File Number



  FORM 12b-25

CUSIP Number




 (Check One) ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR
  For Period Ended:  March 31, 2022
  ¨     Transition Report on Form 10-K
  ¨     Transition Report on Form 20-F
  ¨     Transition Report on Form 11-K
  ¨     Transition Report on Form 10-Q
  For the Transition Period Ended:


Read Instruction (on back page) Before Preparing Form. Please print or type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. 


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A


Kiora Pharmaceuticals, Inc.
Full Name of Registrant
Former Name if Applicable
1371 East 2100 South, Suite 200
Salt Lake City, Utah 84105
Address of Principal Executive Office (Street and Number)
City, State and Zip Code







 PART II — RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)


  (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form  20-F, Form 11-K, Form N-CEN or Form  N-CSR, or portion thereof, will be filed  on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the  prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period.


Kiora Pharmaceuticals, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) in a timely manner without unreasonable effort and expense due to unanticipated delays experienced by the Company in completing its financial statements and other disclosures in the Form 10-Q, primarily due to an assessment of contingent consideration liability. As a result, the Company is still in the process of compiling required information to complete the Form 10-Q and requires additional time to complete its review of the financial statements for the quarter ended March 31, 2022 to be incorporated in the Form 10-Q. The Company presently anticipates that it will file the Form 10-Q before the fifth calendar day following the prescribed due date. 







(1) Name and telephone number of person to contact in regard to this notification


Brian M. Strem, Ph.D.   (781)   788-9043
(Name)   (Area Code)   (Telephone Number)


(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). x Yes   ¨ No


(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

x Yes   ¨ No


If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


For the reasons stated above in Part III, the Company cannot reasonably estimate at this time the anticipated changes to its results of operations. Upon completion of the contingent consideration evaluation, the Company will be able to determine the changes, if any, that such assessment of contingent consideration will have on its results of operations.


Forward-Looking Statements


Certain matters discussed in this Form 12b-25 constitute forward-looking statements within the meaning of the federal securities laws. All statements contained in this Form 12b-25 that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management’s current expectation and include, but are not limited to, statements regarding our beliefs and expectations relating to the filing of the Form 10-Q and the results of the ongoing review.


These forward-looking statements are not guarantees of future results and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond our control. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to file its Form 10-Q within the five-day extension permitted by the rules of the U.S. Securities and Exchange Commission, and the possibility that the ongoing audit may identify errors or control deficiencies in the Company’s accounting practices. We disclaim and do not undertake any obligation to update or revise any forward-looking statement in this report, except as required by applicable law or regulation.





Kiora Pharmaceuticals, Inc.

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.


Date: May 17, 2022 By: /s/ Brian M. Strem, Ph.D.  
    Brian M. Strem, Ph.D.  
    President and Chief Executive Officer  



VIOLATIONS (SEE 18 U.S.C. 1001).